

Frank A Sinicrope

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3787593/publications.pdf>

Version: 2024-02-01

133
papers

16,393
citations

28272

55
h-index

15730

125
g-index

134
all docs

134
docs citations

134
times ranked

25944
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
2	Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3219-3226.	1.6	1,352
3	Towards the introduction of the "Immunoscore"™ in the classification of malignant tumours. <i>Journal of Pathology</i> , 2014, 232, 199-209.	4.5	1,151
4	The Role of Autophagy in Cancer: Therapeutic Implications. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1533-1541.	4.1	1,018
5	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	4.4	676
6	DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy. <i>Journal of the National Cancer Institute</i> , 2011, 103, 863-875.	6.3	469
7	Effect of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Cetuximab on Survival Among Patients With Resected Stage III Colon Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 1383.	7.4	412
8	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 1808-1825.	9.4	388
9	Association Between Molecular Subtypes of Colorectal Cancer and Patient Survival. <i>Gastroenterology</i> , 2015, 148, 77-87.e2.	1.3	342
10	Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2015, 16, 30.	3.0	309
11	Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma. <i>Gastroenterology</i> , 2009, 137, 1270-1279.	1.3	273
12	Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes. <i>Gastroenterology</i> , 2015, 148, 88-99.	1.3	273
13	Prognostic Impact of Deficient DNA Mismatch Repair in Patients With Stage III Colon Cancer From a Randomized Trial of FOLFOX-Based Adjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 3664-3672.	1.6	233
14	Molecular Pathways: Microsatellite Instability in Colorectal Cancer: Prognostic, Predictive, and Therapeutic Implications. <i>Clinical Cancer Research</i> , 2012, 18, 1506-1512.	7.0	217
15	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw272.	6.3	201
16	Prognostic Impact of Microsatellite Instability and DNA Ploidy in Human Colon Carcinoma Patients. <i>Gastroenterology</i> , 2006, 131, 729-737.	1.3	195
17	Obesity Is an Independent Prognostic Variable in Colon Cancer Survivors. <i>Clinical Cancer Research</i> , 2010, 16, 1884-1893.	7.0	191
18	Lynch Syndrome—Associated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 764-773.	27.0	183

#	ARTICLE	IF	CITATIONS
19	Increasing Incidence of Early-Onset Colorectal Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1547-1558.	27.0	165
20	Role of cyclooxygenase-2 in colorectal cancer. <i>Cancer and Metastasis Reviews</i> , 2004, 23, 63-75.	5.9	163
21	Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. <i>Cancer</i> , 2013, 119, 1528-1536.	4.1	141
22	Patient and Tumor Characteristics and BRAF and KRAS Mutations in Colon Cancer, NCCTG/Alliance N0147. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	140
23	DPYD Variants as Predictors of 5-fluorouracil Toxicity in Adjuvant Colon Cancer Treatment (NCCTG) Tj ETQq1 1 0.784314 rgBT /Overlo	6.3	136
24	Autophagy modulation for cancer therapy. <i>Cancer Biology and Therapy</i> , 2011, 11, 169-176.	3.4	130
25	Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. <i>Gastroenterology</i> , 1999, 117, 350-358.	1.3	129
26	<i>KRAS</i> Codon 12 and 13 Mutations in Relation to Disease-Free Survival in <i>BRAF</i> "Wild-Type Stage III Colon Cancers from an Adjuvant Chemotherapy Trial (N0147 Alliance). <i>Clinical Cancer Research</i> , 2014, 20, 3033-3043.	7.0	129
27	Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. <i>Autophagy</i> , 2010, 6, 256-269.	9.1	123
28	Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. <i>Cancer Biology and Therapy</i> , 2013, 14, 100-107.	3.4	122
29	BH3 Mimetic ABT-737 Potentiates TRAIL-Mediated Apoptotic Signaling by Unsequestering Bim and Bak in Human Pancreatic Cancer Cells. <i>Cancer Research</i> , 2008, 68, 2944-2951.	0.9	115
30	Obesity and Breast Cancer Prognosis: Weight of the Evidence. <i>Journal of Clinical Oncology</i> , 2011, 29, 4-7.	1.6	113
31	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 379.	7.1	104
32	Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 651-658.	4.4	99
33	Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer. <i>Molecular Cancer Research</i> , 2018, 16, 378-389.	3.4	99
34	Racial Differences in <i>BRAF</i> / <i>KRAS</i> Mutation Rates and Survival in Stage III Colon Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv186.	6.3	98
35	p62/Sequestosome-1 Up-regulation Promotes ABT-263-induced Caspase-8 Aggregation/Activation on the Autophagosome. <i>Journal of Biological Chemistry</i> , 2013, 288, 33654-33666.	3.4	92
36	Serrated Colon Polyps as Precursors to Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 760-767.	4.4	91

#	ARTICLE	IF	CITATIONS
37	Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis Is Inhibited by Bcl-2 but Restored by the Small Molecule Bcl-2 Inhibitor, HA 14-1, in Human Colon Cancer Cells. <i>Clinical Cancer Research</i> , 2004, 10, 8284-8292.	7.0	87
38	An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis. <i>Gut</i> , 2016, 65, 286-295.	12.1	86
39	Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737. <i>Clinical Cancer Research</i> , 2008, 14, 8132-8142.	7.0	84
40	BH3 Mimetic Obatoclox Enhances TRAIL-Mediated Apoptosis in Human Pancreatic Cancer Cells. <i>Clinical Cancer Research</i> , 2009, 15, 150-159.	7.0	84
41	Prognostic Impact of FoxP3+ Regulatory T Cells in Relation to CD8+ T Lymphocyte Density in Human Colon Carcinomas. <i>PLoS ONE</i> , 2012, 7, e42274.	2.5	84
42	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021, 39, 642-651.	1.6	84
43	Association of DNA Mismatch Repair and Mutations in <i>BRAF</i> and <i>KRAS</i> With Survival After Recurrence in Stage III Colon Cancers. <i>JAMA Oncology</i> , 2017, 3, 472.	7.1	82
44	Clinical implications of microsatellite instability in sporadic colon cancers. <i>Current Opinion in Oncology</i> , 2009, 21, 369-373.	2.4	80
45	Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. <i>Molecular Carcinogenesis</i> , 2006, 45, 447-454.	2.7	79
46	DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 174-177.	27.6	75
47	Prognostic Impact of Bim, Puma, and Noxa Expression in Human Colon Carcinomas. <i>Clinical Cancer Research</i> , 2008, 14, 5810-5818.	7.0	74
48	HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. <i>International Journal of Cancer</i> , 2004, 108, 540-548.	5.1	73
49	Inhibition of mTOR Kinase by AZD8055 Can Antagonize Chemotherapy-induced Cell Death through Autophagy Induction and Down-regulation of p62/Sequestosome 1. <i>Journal of Biological Chemistry</i> , 2011, 286, 40002-40012.	3.4	71
50	Microsatellite Instability Accounts for Tumor Site-Related Differences in Clinicopathologic Variables and Prognosis in Human Colon Cancers. <i>American Journal of Gastroenterology</i> , 2006, 101, 2818-2825.	0.4	70
51	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). <i>Clinical Cancer Research</i> , 2015, 21, 5294-5304.	7.0	70
52	Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. <i>Journal of Clinical Oncology</i> , 2022, 40, 2735-2750.	1.6	62
53	Prognostic Impact of Body Mass Index Stratified by Smoking Status in Patients With Esophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 4561-4567.	1.6	61
54	MiR-139-5p as a novel serum biomarker for recurrence and metastasis in colorectal cancer. <i>Scientific Reports</i> , 2017, 7, 43393.	3.3	61

#	ARTICLE	IF	CITATIONS
55	Mutation-specific antibody detects mutant BRAF ^{V600E} protein expression in human colon carcinomas. <i>Cancer</i> , 2013, 119, 2765-2770.	4.1	60
56	A Bax-Mediated Mechanism for Obatoclox-Induced Apoptosis of Cholangiocarcinoma Cells. <i>Cancer Research</i> , 2010, 70, 1960-1969.	0.9	58
57	Aspirin and Colorectal Cancer: Back to the Future. <i>Clinical Cancer Research</i> , 2014, 20, 1087-1094.	7.0	58
58	Intertumoral Heterogeneity of CD3+ and CD8+ T-Cell Densities in the Microenvironment of DNA Mismatch-Repair-Deficient Colon Cancers: Implications for Prognosis. <i>Clinical Cancer Research</i> , 2019, 25, 125-133.	7.0	57
59	Beclin 1 and UVRAG Confer Protection from Radiation-Induced DNA Damage and Maintain Centrosome Stability in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e100819.	2.5	57
60	Title is missing!. , 2017, , .		56
61	Prognostic impact of deficient mismatch repair (dMMR) in 7,803 stage II/III colon cancer (CC) patients (pts): A pooled individual pt data analysis of 17 adjuvant trials in the ACCENT database.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3507-3507.	1.6	53
62	BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts. <i>Oncogene</i> , 2019, 38, 6752-6766.	5.9	52
63	Association of Obesity With DNA Mismatch Repair Status and Clinical Outcome in Patients With Stage II or III Colon Carcinoma Participating in NCCTG and NSABP Adjuvant Chemotherapy Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 406-412.	1.6	51
64	Epidermal Growth Factor Receptor Signaling Is Up-regulated in Human Colonic Aberrant Crypt Foci. <i>Cancer Research</i> , 2006, 66, 5656-5664.	0.9	50
65	Colorectal cancer prevention: Is an ounce of prevention worth a pound of cure?. <i>Seminars in Oncology</i> , 2005, 32, 24-34.	2.2	49
66	Implications of mismatch repair-deficient status on management of early stage colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2015, 6, 676-84.	1.4	49
67	Sulindac sulfide-induced apoptosis is enhanced by a small-molecule Bcl-2 inhibitor and by TRAIL in human colon cancer cells overexpressing Bcl-2. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1475-1483.	4.1	48
68	The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism. <i>Journal of Biological Chemistry</i> , 2015, 290, 23838-23849.	3.4	46
69	Association between Body Mass Index and Mortality for Colorectal Cancer Survivors: Overall and by Tumor Molecular Phenotype. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1229-1238.	2.5	44
70	Eflornithine plus Sulindac for Prevention of Progression in Familial Adenomatous Polyposis. <i>New England Journal of Medicine</i> , 2020, 383, 1028-1039.	27.0	43
71	Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells. <i>Oncotarget</i> , 2016, 7, 20080-20092.	1.8	43
72	Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability. <i>Clinical Cancer Research</i> , 2006, 12, 2738-2744.	7.0	42

#	ARTICLE	IF	CITATIONS
73	Proapoptotic Bad and Bid Protein Expression Predict Survival in Stages II and III Colon Cancers. <i>Clinical Cancer Research</i> , 2008, 14, 4128-4133.	7.0	41
74	Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. <i>Clinical Colorectal Cancer</i> , 2014, 13, 100-109.	2.3	41
75	MSH3 Mismatch Repair Protein Regulates Sensitivity to Cytotoxic Drugs and a Histone Deacetylase Inhibitor in Human Colon Carcinoma Cells. <i>PLoS ONE</i> , 2013, 8, e65369.	2.5	41
76	Association Study of the let-7 miRNA-Complementary Site Variant in the 3' UTR of the KRAS Gene in Stage III Colon Cancer (NCCTG N0147 Clinical Trial). <i>Clinical Cancer Research</i> , 2014, 20, 3319-3327.	7.0	40
77	Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 3015-3027.	4.1	36
78	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa023.	2.9	36
79	Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. <i>International Journal of Cancer</i> , 2019, 144, 2161-2168.	5.1	34
80	Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance). <i>Oncologist</i> , 2016, 21, 1509-1521.	3.7	33
81	Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. <i>International Journal of Cancer</i> , 2007, 120, 1232-1238.	5.1	32
82	Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 300.	3.7	32
83	Sessile Serrated Polyps and Colon Cancer Prevention. <i>Cancer Prevention Research</i> , 2017, 10, 270-278.	1.5	31
84	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	6.3	25
85	Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer. <i>Future Oncology</i> , 2011, 7, 467-474.	2.4	24
86	Randomized trial of FOLFOX alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient DNA mismatch repair or microsatellite instability (ATOMIC). <i>Journal of Clinical Oncology</i> , 2021, 39, 1071-1080.	10.5	10
87	Advances in Chemotherapy for Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 808-821.	4.4	22
88	Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells. <i>Molecular Cancer Research</i> , 2015, 13, 659-669.	3.4	22
89	Sessile Serrated Polyps are Precursors of Colon Carcinomas With Deficient DNA Mismatch Repair. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1056-1059.	4.4	22
90	Marine omega-3 fatty acid intake and survival of stage III colon cancer according to tumor molecular markers in NCCTG Phase III trial N0147 (Alliance). <i>International Journal of Cancer</i> , 2019, 145, 380-389.	5.1	22

#	ARTICLE	IF	CITATIONS
91	Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients. <i>Cancer</i> , 2010, 116, 1691-1698.	4.1	20
92	Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells. <i>Cancer Letters</i> , 2007, 251, 237-246.	7.2	19
93	Evaluation of Difluoromethylornithine for the Chemoprevention of Barrett's Esophagus and Mucosal Dysplasia. <i>Cancer Prevention Research</i> , 2011, 4, 829-839.	1.5	19
94	Association of beclin 1 expression with response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal carcinoma. <i>International Journal of Cancer</i> , 2015, 137, 1498-1502.	5.1	19
95	A dose-finding study of aspirin for chemoprevention utilizing rectal mucosal prostaglandin E(2) levels as a biomarker. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2002, 11, 275-9.	2.5	19
96	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021, 144, 101-112.	2.8	18
97	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. <i>International Journal of Cancer</i> , 2016, 139, 986-995.	5.1	16
98	Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia. <i>Cancer Prevention Research</i> , 2021, 14, 573-580.	1.5	16
99	Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma. <i>International Journal of Cancer</i> , 2016, 139, 1626-1631.	5.1	15
100	Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004, 13, 920-7.	2.5	15
101	Serrated polyps of the colon. <i>F1000 Medicine Reports</i> , 2010, 2, 89.	2.9	14
102	Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms. <i>Cancer Prevention Research</i> , 2019, 12, 821-830.	1.5	13
103	Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients: A pooled analysis of three adjuvant trials. <i>European Journal of Cancer</i> , 2022, 166, 100-111.	2.8	13
104	Combining Molecular Markers With the TNM Staging System to Improve Prognostication in Stage II and III Colon Cancer: Are We Ready Yet?. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1616-1618.	6.3	11
105	Prognostic Impact of Deficient DNA Mismatch Repair and KRAS and BRAF V600E Mutations in Patients with Lymph-Node-Positive Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2014, 10, 346-353.	0.5	11
106	Physical Activity and Outcomes in Patients with Stage III Colon Cancer: A Correlative Analysis of Phase III Trial NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 696-703.	2.5	11
107	Tumor-Infiltrating Lymphocytes for Prognostic Stratification in Nonmetastatic Colon Cancer: Are We There Yet?. <i>JAMA Oncology</i> , 2021, 7, 969.	7.1	11
108	EUS fine-needle pancreatic core biopsy can determine eligibility for tumor-agnostic immunotherapy. <i>Endoscopy International Open</i> , 2018, 06, E1278-E1282.	1.8	10

#	ARTICLE	IF	CITATIONS
109	Evaluating the Combination of Microsatellite Instability and Mutation in BRAF as Prognostic Factors for Patients With Colorectal Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 391-394.	4.4	10
110	Intratumoral CD3+ and CD8+ T-Cell Densities in Patients With DNA Mismatch Repair-Deficient Metastatic Colorectal Cancer Receiving Programmed Cell Death-1 Blockade. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	3.0	9
111	Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147. <i>Journal of Clinical Oncology</i> , 2014, 32, 3525-3525.	1.6	9
112	The Future Role of the Gastroenterologist in Digestive Oncology: An International Perspective. <i>Gastroenterology</i> , 2011, 141, e13-e21.	1.3	7
113	Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2717-2723.e3.	4.4	7
114	Irreversible JNK blockade overcomes PD-L1-mediated resistance to chemotherapy in colorectal cancer. <i>Oncogene</i> , 2021, 40, 5105-5115.	5.9	7
115	Vasodilator-Stimulated Phosphoprotein Biomarkers Are Associated with Invasion and Metastasis in Colorectal Cancer. <i>Biomarkers in Cancer</i> , 2018, 10, 1179299X1877455.	3.6	5
116	Advances in the therapy of BRAF ^{V600E} metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 823-829.	2.4	5
117	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , 2020, 4, 116-127.	3.0	4
118	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab070.	2.9	4
119	Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC). <i>Journal of Clinical Oncology</i> , 2019, 37, 3520-3520.	1.6	4
120	Aflibercept and Its Role in the Treatment of Colorectal Cancer—Letter. <i>Clinical Cancer Research</i> , 2013, 19, 6057-6057.	7.0	3
121	Novel methylated DNA markers accurately discriminate Lynch syndrome associated colorectal neoplasia. <i>Epigenomics</i> , 2020, 12, 2173-2187.	2.1	3
122	Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147). <i>Journal of Clinical Oncology</i> , 2015, 33, 3590-3590.	1.6	3
123	O-0029 Prognostic Impact of DNA Mismatch Repair Status and BRAF Mutations in Stage III Colon Cancer Patients Treated in a Phase III Study of Adjuvant Folfox Alone or Combined with Cetuximab: NCCTG N0147. <i>Annals of Oncology</i> , 2012, 23, iv17-iv18.	1.2	2
124	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 3506-3506.	1.6	2
125	Is ursodeoxycholic acid effective for the prevention of colorectal adenoma recurrence?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2005, 2, 512-513.	1.7	1
126	Clinical Relevance of Apoptotic Regulatory Proteins in Colorectal Cancers. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 111-117.	0.5	1

#	ARTICLE	IF	CITATIONS
127	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 404-411.	2.5	1
128	Heterogeneity in the lymphocytic infiltration of deficient DNA mismatch repair colon cancers. <i>Oncotarget</i> , 2018, 9, 36722-36723.	1.8	1
129	Current status of colorectal cancer chemoprevention. <i>Current Colorectal Cancer Reports</i> , 2007, 3, 39-48.	0.5	0
130	Mutation in BRAF V600E: A Poor Prognostic Marker in Stage III Colon Cancers With Deficient MMR?â€”Reply. <i>JAMA Oncology</i> , 2017, 3, 1285.	7.1	0
131	A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147.. <i>Journal of Clinical Oncology</i> , 2012, 30, 446-446.	1.6	0
132	Use of FoxP3+ and cytotoxic CD8+ T lymphocytes to identify a patient subgroup with a favorable prognosis similar to colon cancers with deficient DNA mismatch (dMMR) repair.. <i>Journal of Clinical Oncology</i> , 2012, 30, 460-460.	1.6	0
133	Barrettâ€™s Esophagus. , 2005, , 346-373.		0